Antiarrhythmics are a critical class of pharmaceuticals used to suppress or prevent disturbances in cardiac rhythm (arrhythmias). In 2026, the management of cardiac health has shifted toward “Precision Electrophysiology,” where antiarrhythmic therapy is increasingly tailored to the patient’s specific ion channel profile and genetic makeup.
1. The Vaughan Williams Classification (Modernized 2026)
The standard way to categorize antiarrhythmics is the Vaughan Williams system, which groups drugs based on their primary mechanism of action on the heart’s electrical action potential.
| Class | Mechanism of Action | Common Examples |
| Class I | Sodium ($Na^+$) Channel Blockers: Slows electrical conduction in the heart muscle. | Quinidine (IA), Lidocaine (IB), Flecainide (IC). |
| Class II | Beta-Blockers: Decreases sympathetic nervous system effects; slows heart rate. | Metoprolol, Bisoprolol, Atenolol. |
| Class III | Potassium ($K^+$) Channel Blockers: Prolongs the time the heart takes to “reset” (repolarization). | Amiodarone, Sotalol, Dofetilide. |
| Class IV | Calcium ($Ca^{2+}$) Channel Blockers: Slows conduction through the AV node. | Verapamil, Diltiazem. |
| Class V | Miscellaneous: Unique mechanisms not covered by the four main classes. | Adenosine, Digoxin, Magnesium Sulfate. |
2. Significance of Antiarrhythmic Manufacturing in India
As of 2026, India’s pharmaceutical sector has pivoted toward “High-Value Innovation,” moving beyond simple generic tablets to complex cardiac therapies.
Critical Care Dominance: India is a leading global supplier of Injectable Antiarrhythmics (like Adenosine and Lidocaine) used in emergency rooms and ICUs worldwide.
Technological Shift: In 2026, Indian manufacturers are utilizing AI-driven formulation to create “Smart Release” tablets that maintain steady drug plasma levels, reducing the risk of proarrhythmia (the drug itself causing a new arrhythmia).
Rare Disease Focus: Recent 2026 launches in India, such as Quinidine Sulphate tablets for rare irregular heartbeat conditions, highlight the industry’s shift toward addressing unmet medical needs.
Global Compliance: Indian cardiac manufacturing units lead the world in USFDA and EU-GMP certifications, ensuring that Indian-made heart medications meet the world’s most rigorous safety standards.
3. Why Healthy Inc. is Your Strategic Cardiac Partner
Sourcing antiarrhythmics requires an absolute focus on Batch Consistency and Technical Purity, as even minor variations can affect heart rhythm. Healthy Inc. acts as your technical gateway:
Strategic Sourcing Hub: We are associated with multiple state-of-the-art manufacturing units featuring dedicated Cardiovascular Lines. Whether you need high-volume Beta-blockers or specialized Class III Injectables, we match you with the right facility.
Pharmacist-Led Technical Vetting: We provide “straight answers” on Bioavailability and Pharmacokinetics. Our team vets every batch to ensure precise dissolution rates, which is critical for cardiac safety.
Regulatory & Dossier Mastery: We simplify international registration by providing full CTD/ACTD dossiers, stability studies for all climate zones, and bioequivalence reports required for global tenders.
Market-Ready Solutions: Through our associated network, we offer flexible Private Labeling (OEM), allowing you to launch your own brand of high-quality cardiac care with professional packaging and documentation.
Showing all 2 results
Amiodarone Tablet
FreeProduct Composition & Available Strengths
We manufacture Amiodarone in standard, internationally recognized strengths to allow for the intensive loading phase and lower maintenance doses required in cardiology.
Active Ingredient Standard Strengths Primary Clinical Target Amiodarone HCl BP / IP / USP 100 mg Low-Dose Maintenance: For fine-tuned long-term rhythm control and geriatric titration. Amiodarone HCl BP / IP / USP 200 mg Standard Therapy: Used for initial institutional oral loading phases and standard daily maintenance. Leflunomide Tablets
FreeProduct Composition & Available Portfolio Strengths
We supply Leflunomide across the complete compendial strength matrix, enabling clinicians to manage both rapid initial loading cycles and long-term low-dose maintenance blocks.
Active Ingredient Monograph Available Strengths Formulation Matrix Delivery System Primary Clinical Application Leflunomide USP / BP / IP 10 mg Oral Solid Film-Coated Tablet Low-Dose Maintenance: Calibrated for mild-to-moderate maintenance blocks or patients exhibiting sensitive hepatic profiles. Leflunomide USP / BP / IP 20 mg Oral Solid Film-Coated Tablet The Core Commercial Volume: First-line international standard daily maintenance dose for active Rheumatoid and Psoriatic Arthritis. Leflunomide USP / BP / IP 100 mg Oral High-Mass Solid Tablet Initial Loading Regimen: High-potency format utilized exclusively for the rapid 3-day initial tissue saturation phase.
